POC Analyser Selection & Setup Checklist

The choice of point-of-care analyser shapes everything that follows — test menu, CLIA status, reagent cost per run, and throughput capacity. Most cholesterol testing startups use CLIA-waived devices, which lets them skip the full CLIA certification process and operate with a significantly cheaper Certificate of Waiver (CoW) at $248 biennial from CMS.

The three analysers that dominate US cholesterol testing startups, ranked by typical entry price:

For UK operators, the Cholestech LDX and Afinion are both CE-marked and UKCA-compliant for in-vitro diagnostic use. The Abbott Afinion's expanded panel (HbA1c, CRP alongside lipids) allows upselling to a more comprehensive metabolic health screen at a premium price point — a useful differentiation for private clinics competing with NHS Health Checks.

Full Equipment Setup Checklist

• POC lipid analyser: CardioChek PA, Cholestech LDX, or Afinion AS100 — $2,000–$18,000 depending on menu breadth
• Lancets (auto-lancing device + sterile lancets): Safety lancets, 28G, $0.08–$0.15 each; BD Microtainer Contact-Activated Lancets recommended
• Capillary collection supplies: Capillary tubes, Microtainers, or direct-to-cassette strips — device-specific
• Refrigerator for reagent storage: Reagents for the Cholestech LDX must be stored 2–8°C; a bar-style mini fridge ($80–$200) works for a mobile unit
• Personal protective equipment: Nitrile gloves (box of 100, $8–$12), face shields, clinical aprons
• Biohazard sharps containers: Wall-mounted or portable; disposal service contract $150–$400/yr
• QC (quality control) materials: High and low QC solutions per the device manufacturer — run before the first patient test each operating day
• Result documentation: Paper log or LIS integration — required for CLIA compliance; result records must be retained for 2 years
• Patient consent forms: Bilingual if serving diverse communities; digital signature capture preferred
• First-aid kit: For vasovagal responses post-finger-prick — standard HSE kit (UK) or OSHA-compliant first aid kit (US)

Mobile Van vs. Clinic-Based Setup

A mobile setup (converted van or minibus) costs more upfront to outfit — typically $30,000–$90,000 for vehicle, fit-out, and graphics — but removes the need for a fixed clinic lease. Established mobile cholesterol testing operators in the US (such as Quest Mobile, which charges $79 for in-home phlebotomy add-on) demonstrate the model is viable at scale. In the UK, corporate wellness providers operating fleet vehicles typically bill £30–£55 per employee for on-site lipid screening days.

A clinic-based setup works better for operators targeting GP referral walk-in traffic, private insurance clients, or community health partnerships. Monthly rent for a single treatment room in a shared healthcare facility (GP surgery annex, community centre, private clinic) runs $500–$2,500/month in the US (£400–£2,000/month in the UK).

What It Costs to Launch: Budget Ranges & Funding Options

A lean mobile or single-room cholesterol testing startup in the US typically requires $45,000–$250,000 in initial capital (£35,000–£190,000 in the UK). The range is wide because the biggest single variable is premises — a mobile van costs $30,000–$90,000 to outfit, while a clinic in a sublet GP room might require just a £500/month agreement with no fit-out spend.

Startup Cost Breakdown

• POC analyser (primary unit): $2,000–$18,000 (£1,600–£14,000) — CardioChek PA to Afinion AS100
• Mobile vehicle or clinic lease deposit + fit-out: $20,000–$120,000 (£15,000–£95,000) — biggest variance driver
• CLIA Certificate of Waiver (US) / CQC registration (UK): $248 biennial (US) · £2,315–£4,635 (UK) — required before first patient
• Professional liability & public indemnity insurance: $3,500–$8,000/yr (£2,800–£6,500/yr)
• Test strips, reagents & consumables (first 3 months): $3,000–$12,000 (£2,500–£9,500)
• Phlebotomist/healthcare assistant wages (first 3 months): $9,000–$25,000 (£7,000–£20,000)
• LIS software, scheduling & billing integration: $1,500–$5,000 (£1,200–£4,000)
• Marketing: website, referral pack, corporate pitch decks: $2,500–$8,000 (£2,000–£6,500)
• Working capital (3 months): $8,000–$30,000 (£6,500–£24,000)

Funding Routes for Cholesterol Testing Startups

In the US, the primary funding route is the SBA 7(a) loan under NAICS code 621511 (Medical Laboratories). The SBA size standard for 621511 is annual revenue under $35 million, meaning virtually all new entrants qualify as small businesses. SBA 7(a) loans cover up to $5 million at fixed or variable rates (prime + 2.75% for loans over $50k), with terms up to 10 years for working capital and up to 25 years for real estate. Our bespoke business plan service includes SBA-formatted executive summaries, lender-ready financial projections, and the NAICS code documentation that lenders request.

Equipment financing is the fastest route for the analyser itself — most medical equipment lenders will finance 80–100% of the POC device cost at 6–10% APR, with 24–60 month terms. This preserves working capital for consumables and staff during the ramp period.

In the UK, the Start Up Loans scheme (British Business Bank) provides up to £25,000 per founder at 6% fixed interest with free mentoring. A two-founder arrangement therefore allows up to £50,000. The NHS England Community Diagnostic Centre programme has also commissioned independent diagnostics providers, creating a contracting pathway that bypasses the need to build direct-to-consumer demand from scratch.

Software & Tools Every Cholesterol Testing Operator Needs

The administrative overhead in a clinical testing business is higher than in most service businesses, because every test result is a medical record with retention, confidentiality, and audit trail requirements. The right software stack cuts this overhead significantly and is increasingly a selling point with corporate wellness buyers who want integrated reporting.

A business plan credible to an SBA lender or NHS procurement team should show that the software stack is already chosen, not "TBD." Avvale's Research + Content package includes a recommended technology stack section tailored to your specific business model.

Licensing & Regulatory Requirements by Jurisdiction

Cholesterol testing is a regulated clinical activity in every major market. The compliance requirements differ significantly between a mobile screening service and a full clinical laboratory, and between CLIA-waived POC testing and laboratory-based analysis. What follows covers the most common setup: a CLIA-waived or equivalent POC service.

United States

• CLIA Certificate of Waiver (CoW): Issued by CMS; required before performing any POC cholesterol test on a human specimen. Apply via Form CMS-116. Biennial fee: $248. Processing time: 4–8 weeks. CLIA-waived analysers include the Cholestech LDX, CardioChek PA, and Afinion AS100.
• State clinical laboratory licence: Required in approximately 23 states (notably New York, California, Florida). NYS CLEP licence costs $485 for initial application; California CDPH lab licence costs $675–$1,680 depending on scope. Processing: 6–12 weeks.
• Phlebotomist state licence: Mandatory in California, Washington, Nevada, and Louisiana. Examination fees $50–$200 via ASCP or NHA. Other states accept national certification without a state-specific licence.
• Business registration + EIN: $50–$500 via Secretary of State; EIN from IRS at no cost (online, same day).
• HIPAA compliance programme: Required for any entity handling protected health information. Setup via software such as Compliancy Group ($299/yr) or HIPAA One ($450/yr). Office for Civil Rights can audit at any time.
• Biohazard waste disposal registration: State environmental agency registration $200–$800/yr; service contract with a licensed medical waste hauler.
• Professional liability (malpractice) insurance: $3,500–$8,000/yr for a small diagnostic services business. Required by most corporate wellness contract procurement departments.

United Kingdom

• CQC registration — Diagnostic and Screening Procedures: Any organisation providing cholesterol testing to the public must register before operating. Submit application to HSCA_Applications@cqc.org.uk. Fee: £2,315–£4,635 depending on service scale. Processing: 10–20 weeks. A Nominated Individual (legally accountable for governance) and a Registered Manager must be appointed and approved.
• UKAS accreditation (ISO 15189): Not legally mandatory for POCT services, but required if tendering for NHS or occupational health contracts above a certain threshold. Initial assessment: £1,500–£5,000+; 6–18 months to achieve. Many operators contract with an accredited laboratory for result confirmation rather than self-accrediting.
• UKCA marking for POC devices: Devices used in the UK must carry UKCA marking (post-Brexit replacement for CE mark) — this is the device manufacturer's responsibility, not the operator's, but you must verify the device is UKCA/CE-marked before purchase.
• ICO registration (UK GDPR): Required for any data controller processing health data. £40–£2,900/yr depending on turnover and headcount. Register at ico.org.uk. Health data is "special category" data; a Data Protection Impact Assessment (DPIA) is required.
• Professional indemnity + public liability insurance: £3,000–£8,000/yr. NHS Frameworks and corporate clients typically require minimum £5M public liability cover.

International Markets

• Canada: IVD devices require a Health Canada Medical Device Licence (Class II–III). Provincial laboratory licensing varies — Ontario, Quebec, and BC have specific lab licensing frameworks. WorkSafe/WSIB coverage required for employees. CLIA equivalent: Ontario Lab Accreditation (OLA) or equivalent provincial body.
• Australia: TGA registration for IVD devices (Class 3 for most lipid analysers). NATA accreditation (ISO 15189) strongly recommended. ABN required. AHPRA registration for any test interpretation by a regulated health practitioner.
• European Union: IVD Regulation (IVDR) EU 2017/746 applies to all diagnostic devices from May 2022. Country-specific business registration. Devices require CE marking under IVDR — significantly more rigorous than the predecessor Directive (IVDD 98/79/EC). Engage a Notified Body early if planning EU market entry.

Revenue Model: Pricing, Margins & Unit Economics

There are three distinct business models in cholesterol testing services, each with different pricing dynamics and margin profiles:

Model 1 — Consumer Direct (B2C)

Pricing benchmarks from named operators as of 2025: LetsGetChecked charges $119 for a heart health panel (cholesterol + CRP); Everlywell charges $99 for a Heart Health Test (total/HDL/LDL/triglycerides + hs-CRP); Quest Diagnostics prices a lipid panel at approximately $176 cash price with in-home phlebotomy add-on at +$79. In the UK, Medichecks offers a finger-prick cholesterol test from £39; HCA Healthcare UK charges from £75 for a clinic-based lipid profile. These benchmarks define the consumer ceiling: direct-to-consumer pricing is being anchored at $49–$179, with at-home kits exerting downward pressure on walk-in clinic rates.

Model 2 — Corporate Wellness (B2B)

Corporate wellness contracts are priced per employee per visit, typically $35–$65 in the US and £30–£55 in the UK. Volume is higher (a single corporate health day might involve 80–200 tests), acquisition cost is effectively zero after contract signature, and the corporate client handles employee communication and scheduling. Most established POC cholesterol operators derive 60–70% of revenue from B2B contracts after year one.

Model 3 — NHS / Insurance Contracting (B2G)

In the UK, NHS England commissions cholesterol testing through its NHS Health Check programme (targeted at adults aged 40–74) and via integrated care boards. Community pharmacy and private provider contracts typically reimburse £10–£25 per test (lower margin than private, but high volume and guaranteed payment). In the US, Medicare reimburses lipid panels under CPT code 80061 at approximately $11–$22 per test depending on locality — suitable for high-volume mobile operators but not a standalone business model.

Unit Economics: Worked Example

A mobile operator running 25 lipid panels per day at a blended average of $75 per test (mix of B2C at $99 and B2B at $45) generates:

• Gross revenue: $75 × 25 × 250 operating days = $468,750/yr
• Cost of consumables: ~$8/test × 6,250 tests = $50,000/yr
• Gross profit: $418,750 (~89% gross margin — unusually high because labour is a fixed cost, not per-test)
• Phlebotomist salary: $55,000/yr
• Vehicle depreciation + fuel + maintenance: $18,000/yr
• Insurance (professional liability + vehicle): $9,000/yr
• Software, waste disposal, overheads: $12,000/yr
• Net profit (Year 1): ~$324,750 pre-tax... Wait — let me recalculate: $418,750 minus $94,000 overheads = $324,750 pre-tax (69%) at full utilisation. Real Year 1 utilisation is typically 55–65%, giving $80,000–$130,000 net profit at the worked example scale.

The key margin lever is utilisation rate — the ratio of paying tests to available slots. Most operators reach breakeven at 40–50% utilisation; profitability climbs steeply above that threshold because fixed costs (vehicle, staff, insurance) don't scale with volume. A business plan that models three utilisation scenarios (conservative 40%, base 60%, optimistic 80%) gives a lender a realistic picture of the risk profile.

Operators that add HbA1c testing (diabetes screening, $25–$45 add-on) alongside the lipid panel increase revenue per visit by 30–50% with no additional setup beyond a compatible analyser (the Afinion AS100 covers both). This is a meaningful differentiator in the medical diagnostic services space where cholesterol testing competes with blood glucose monitoring businesses for the same wellness-focused customer.

The Cholesterol Testing Market in 2025–2026

The global cholesterol testing products and services market was valued at $21.64 billion in 2025 and is forecast to reach $37.32 billion by 2032, growing at 8.1% CAGR, according to Skyquest Technology Consulting. A parallel estimate from Market Research Future puts the market at $48.96 billion by 2034 at an 8.3% CAGR, reflecting minor scope differences between the studies.

North America accounts for approximately 35% of global market revenue — translating to roughly $7.5 billion in US and Canada combined for 2025, per Grand View Research's regional outlook. The UK market, sitting within the larger European diagnostics segment, generates an estimated £1.2–£1.8 billion in cholesterol-related diagnostics annually (Avvale estimate, derived from applying the UK's NHS and private diagnostics share to the European regional figure).

What's Driving Demand

The four structural demand drivers for cholesterol testing services are not cyclical — they compound over time:

• Cardiovascular disease burden: CVD remains the leading cause of death globally. The American Heart Association estimates 126 million US adults have some form of CVD; regular cholesterol monitoring is the primary preventive screen. The UK's NHS Health Check programme targets 1.8 million adults per year for cholesterol and metabolic screening.
• Rising obesity and diabetes prevalence: Both conditions elevate LDL cholesterol and reduce HDL — creating a co-morbid demand multiplier. The CDC estimates 42% of US adults are obese as of 2024, up from 31% in 2000. Each percentage point of obesity prevalence increases demand for metabolic screening.
• Employer wellness programmes: Corporate healthcare costs in the US exceed $13,000 per employee per year. Employers with high chronic disease burden face escalating premiums; preventive screening programmes that identify high-risk employees early reduce long-term insurance costs. This creates a structurally funded B2B channel for cholesterol testing operators.
• Consumer health self-monitoring: At-home and direct-to-consumer testing grew significantly post-2020. LetsGetChecked, Everlywell, and Thriva (UK) have normalised consumer purchasing of diagnostic tests online. This lowers acquisition cost for new entrants selling direct-to-consumer and expands the addressable market beyond GP referral pathways.

Where the Market Is Heading: POC vs. Lab-Based

POC testing (the model most startups use) is the fastest-growing segment — growing at over 10% annually versus 5–6% for traditional laboratory-based testing. The drivers are speed (finger-prick results in 3–5 minutes vs. 24–48 hours for lab panels), lower cost per test at low volumes, and the ability to deliver results during the same consultation. For a business plan, this means the POC operator model is better positioned for growth than a model dependent on outsourcing sample analysis to a reference laboratory.

Sample Business Plan Preview

Here is an extract from a cholesterol testing services business plan produced by Avvale — showing the calibre of narrative and numbers that accompany our bespoke work:

What's in the Cholesterol Testing Services Business Plan Template

Every Avvale business plan template includes these sections, pre-structured for your specific business type:

• Executive Summary — Written to hook a lender or investor in under 90 seconds. Includes your market opportunity, funding ask, projected Year 1 revenue, and breakeven timeline.
• Company Overview — Legal structure (LLC, Ltd, sole trader), registered address, ownership split, and founding story. Includes guidance on structure choice for a clinical business.
• Industry & Market Analysis — Cholesterol testing market size ($21.6B global, 8.1% CAGR), growth drivers, POC vs. lab-based segment trends, and competitor benchmarks (LetsGetChecked, Everlywell, Quest, Medichecks).
• Customer Analysis — Consumer (B2C), corporate wellness (B2B), and NHS/insurance (B2G) segment profiles, including spending triggers, willingness-to-pay benchmarks, and channel-by-channel acquisition assumptions.
• Competitor Analysis — Local and national competitor mapping, pricing comparison, service gap analysis, and your differentiation strategy.
• Operations Plan — CLIA/CQC compliance workflow, analyser selection rationale, phlebotomy protocols, QC schedule, biohazard waste disposal process, and HIPAA/GDPR data handling procedures.
• Marketing Plan — Corporate wellness pitch sequence, GP referral network development, direct consumer acquisition (Google Ads, Facebook health audiences), and referral programme structure.
• Management Team — Founder bio, key hire plan (phlebotomist, admin), advisory board (clinical governance), and CQC Nominated Individual / Registered Manager roles.

Our Research + Content package ($300/£250) and Bespoke Plan ($1,000/£800) both include a 5-year Excel financial model: monthly P&L, cash flow statement, balance sheet, break-even analysis, utilisation scenario modelling (conservative / base / optimistic), and SBA-formatted capital requirements schedule. The bespoke plan also includes a CLIA/CQC compliance checklist specific to your chosen business model.

See related templates: Medical Diagnostic Services Business Plan | Health & Wellness Business Plan Template | All Free Business Plan Templates

Frequently Asked Questions